MannKind Corporation (MNKD): What’s the Latest: New Insulin Inhaler, Rating Reiterated by Zacks, Matthew J. Pfeffer & More

Editor’s Note: MannKind Corporation (NASDAQ:MNKD), Pfizer Inc. (NYSE:PFE), Avanir Pharmaceuticals Inc (NASDAQ:AVNR), Merck & Co., Inc. (NYSE:MRK)

For Diabetics, a New Insulin Inhaler Could Replace Shots as Early as 2014 (Businessweek)
The long promise of insulin that diabetics can inhale appears to be moving closer to the market. An inhalable insulin powder called Afrezza showed positive results for controlling diabetes in a late-stage clinical trial, the drug’s maker, MannKind Corporation (NASDAQ:MNKD), reported today. Pharmaceutical companies have been working on inhalable insulin for a long time on the theory that diabetics would prefer to puff on an inhaler than give themselves a shot. In 2007, Pfizer (PFE) stopped selling its Exubera insulin powder because of weak sales after less than two years on the market. Exubera never gained traction, largely because insurers wouldn’t pay for it, saying it was too expensive and didn’t work for many patients. Eli Lilly & Co. (LLY) and Novo Nordisk (NVO) both ended inhaled insulin research programs in 2008.

MannKind Corporation (NASDAQ:MNKD)MannKind Corp. Rating Reiterated by Zacks (MNKD) (Watch List News)
MannKind Corporation (NASDAQ:MNKD)‘s stock had its “neutral” rating reaffirmed by Zacks in a research report issued to clients and investors on Wednesday, AR Network reports. They currently have a $7.25 target price on the stock. Zacks‘ price objective points to a potential upside of 5.69% from the stock’s previous close. Zacks‘ analyst wrote, “MannKind’s second quarter 2013 net loss of $0.16 per share was narrower than the year-ago loss of $0.23 but wider than the Zacks Consensus Estimate of a loss of $0.15. We expect investor focus to remain on Afrezza.

Investors Purchase High Volume of MannKind Corp. Put Options (MNKD) (Watch List News)
Shares of MannKind Corporation (NASDAQ:MNKD) was the recipient of unusually large options trading activity on Monday. Traders acquired 11,596 put options on the company, Stock Ratings Network reports.This is an increase of approximately 114% compared to the average volume of 5,418 put options. In other MannKind Corp. news, CFO Matthew J. Pfeffer sold 10,000 shares of MannKind Corp. stock in a transaction that occured on Thursday, August 1st. The stock was sold at an average price of $8.00, for a total transaction of $80,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission.

Healthcare Stocks in Spotlight – MannKind Corporation (NASDAQ:MNKD), Pfizer Inc. (NYSE:PFE), Avanir Pharmaceuticals Inc (NASDAQ:AVNR), Merck & Co., Inc. (NYSE:MRK) (Techsonian)
King Penny Stocks is an elite financial community for investors and traders alike who are looking to potentially gain financial freedom through the markets on undervalued companies and “in-play” momentum penny stocks. Today We bring special trend analysis of following stocks: MannKind Corporation (NASDAQ:MNKD), Pfizer Inc. (NYSE:PFE), Avanir Pharmaceuticals Inc (NASDAQ:AVNR), Merck & Co., Inc. (NYSE:MRK). MannKind Corporation reported the gain of +17.93% to $8.09 in the mid-day trading session with the total traded volume of 31.37 million shares more than the average volume of 6.37 million. MNKD has market cap of 2.45 billion and its beta value stands at 1.41 times. MannKind Corporation (MannKind) is a development-stage biopharmaceutical company.

MannKind Diabetes Drug Tops Expectations in Study, Shares Soar (Fox Business)
Shares of MannKind Corporation (NASDAQ:MNKD) climbed 20% Wednesday morning after the company revealed positive late-stage trial results for its experimental diabetes drug. The Valencia, Calif.-based drug developer said two Phase III clinical studies for Afrezza, an ultra rapid-acting mealtime insulin therapy administered through MannKind’s next-generation inhaler, met their primary endpoints. The results “will form the basis of an amendment to our new drug application for AFREZZA, which we expect to submit to the Food and Drug Administration early in the fourth quarter of this year,” MannKind CEO Alfred Mann said in a statement.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Click here to Read Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 74 percentage points in 2.5 years. Our beta is only 1.2 (download a FREE newsletter and see the details inside)

Lists

Best Selling Magazines in the World

Shortest People in History

The Most Celebrated Holidays in the World

Most Expensive Handbag Brands in the World

Top Selling Comic Book Issues of this Century

The Most Powerful Women in Politics

Best Paid DJs

Most Rebellious Female Artists

Best Paid TV Actresses of 2014

Best Paid Actors of 2014

Most Expensive Horses in the World

Tallest People Ever

Most Encouraging Feminist Celebrities

Best Paid Supermodels of 2014

Top 10 Suburbs for Retirement in 2015

10 Wealthiest Cities in America

Top 10 TED Talks for Entrepreneurs

Best TED Talks on Education

25 Most Dangerous Places to Live in America

Top 10 Ski Resorts in the United States – 2014 List

Top 10 Most Remote Places in the World

Most Visited Museums in the United States

Wealthiest Photographers in the World

Most Famous Gay Athletes

The World’s Most Famous Circuses

Best Hair Stylists

Most Popular NASCAR Drivers

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!